Back to Previous Page

Anti-PTPRT Antibody, clone 1F7 clone 1F7, from mouse

ITEM#: 3042-MABS1158

MFR#: MABS1158

Receptor-type tyrosine-protein phosphatase T (EC 3.1.3.48; UniProt O14522; also known as R-PTP-T, Receptor protein tyrosine phosphatase, Receptor-type tyrosine-protein phosphatase rho, RPTP-rho, RPTPrho) is encoded by the PTPRT (also known as KIAA028

Receptor-type tyrosine-protein phosphatase T (EC 3.1.3.48; UniProt O14522; also known as R-PTP-T, Receptor protein tyrosine phosphatase, Receptor-type tyrosine-protein phosphatase rho, RPTP-rho, RPTPrho) is encoded by the PTPRT (also known as KIAA0283) gene (Gene ID 11122) in human. RPTPrho/PTPRT is a member of the R2B subfamily of receptor-type protein tyrosine phosphatases (R-PTPs). Known RPTPrho/PTPRT substrates include BCR (Tyr177), paxillin (Tyr188), and STAT3 (Tyr705). In addition, in vitro pull-downs and cell-free dephosphorylation assays also suggest cadherin and catenin family of cell adhesion molecules as physiological substrates of RPTPrho/PTPRT. PTPRT is the single most commonly mutated PTPR gene in all sequenced human cancers, with the highest PTPRT mutation frequency found in cutaneous melanoma. Among 16 tumor types examined, 37.9% of PTPRT mutations are found in the catalytic (PTPase) domain and 33.0% in the extracellular fibronectin type III-like (FN3) domain. In head and neck squamous cell carcinoma (HNSCC), 45.5% PTPRT mutations are located in the PTPase domain, leading to up-regulated STAT3 phosphorylation in HNSCC tumors.